Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + nab-paclitaxel + carboplatin + epirubicin + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination regimen is a neoadjuvant therapy being investigated for early-stage, treatment-naive triple-negative breast cancer (TNBC). It consists of the PD-1 inhibitor sintilimab administered alongside a sequential chemotherapy backbone. The chemotherapy includes four cycles of albumin-bound paclitaxel (nab-paclitaxel) and carboplatin, followed by four cycles of epirubicin and cyclophosphamide. Sintilimab is a recombinant humanized IgG4 monoclonal antibody that binds to the PD-1 receptor, blocking its interaction with PD-L1 and PD-L2 to restore T-cell antitumor activity. This regimen is often studied in combination with stereotactic body radiotherapy (SBRT) to enhance immunogenicity and improve pathological complete response (pCR) rates in high-risk TNBC patients.
- Other names
- PD-1 inhibitor + chemotherapy-West China Hospital-triple-negative breast cancerSintilimab + nab-paclitaxel + carboplatin + epirubicin + cyclophosphamideSintilimab + ChemotherapySintilimab plus nab-paclitaxel, carboplatin, epirubicin, and cyclophosphamide
02
Targets
TOP2A (DNA topoisomerase II)PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on sintilimab + nab-paclitaxel + carboplatin + epirubicin + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + nab-paclitaxel + carboplatin + epirubicin + cyclophosphamide.